Litigation Details for Wells v. Boehringer Ingelheim Pharmaceuticals, Inc., etal (N.D. Ohio 2020)
✉ Email this page to a colleague
Wells v. Boehringer Ingelheim Pharmaceuticals, Inc., etal (N.D. Ohio 2020)
Docket | ⤷ Try a Trial | Date Filed | 2020-01-06 |
Court | District Court, N.D. Ohio | Date Terminated | |
Cause | 28:1332 Diversity-Product Liability | Assigned To | James S. Gwin |
Jury Demand | Plaintiff | Referred To | |
Patents | 6,020,001; 9,000,002 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Wells v. Boehringer Ingelheim Pharmaceuticals, Inc., etal
Biologic Drugs cited in Wells v. Boehringer Ingelheim Pharmaceuticals, Inc., etal
Details for Wells v. Boehringer Ingelheim Pharmaceuticals, Inc., etal (N.D. Ohio 2020)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2020-01-06 | 1 | Complaint | Document Case: 1:20-cv-00017-JG Doc #: 1 Filed: 01/06/20 1 of 48. PagelD # 1 IN THE UNITED STATES DISTRICT…amp; Hanburys Ltd. was awarded Patent No. 4,128,658 by the U.S. Patent and Trademark Office in December…successor-in-interest to the companies that initially developed, patented, and commercialized the molecule known as ranitidine | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |